Sonic Healthcare sold its 85 percent stake in GLP. Abbott has acquired the remaining 15 percent interest in the German firm and will collaborate with Sonic in the long term.
The company's patent related to labeled nucleotides for use as diagnostic tools and as therapeutic agents has been invalidated.
According to the company, it has shipped more than 1,700 of the IVD analyzer platforms since launching sales globally in 2017.
The test, called Fujifilm SILVAMP TB LAM, was found to be about 30 percent more sensitive than the Alere Determine TB LAM Ag test from Abbott.
After conducting a head-to-head comparison with competing instruments, clinicians selected the Abbott iStat instrument to monitor blood clotting during surgical interventions.
Researchers reported that elevated high-sensitivity troponin I is strongly associated with increased risk of cardiovascular disease in some populations.
The firm said that its nucleic acid amplification test provides viral load measurements of HIV type 1 groups M/N and O, and HIV-2 within 70 minutes
Abbott's test is designed to detect two proteins — GFAP and UCH-L1 — that are released from the brain into the bloodstream following brain injury.
The firm said its new molecular platform, which offers random-access testing, high throughput, and a broad menu has the potential to replace multiple instruments in molecular labs.